RenovoRxRNXT -2.41%31 EBITDA Margin % is -615.99% as of Mar. 2026. GuruFocus rates RNXT with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 944 Biotechnology companies, RenovoRx ranks worse than 78.39% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. RenovoRx's EBITDA for the
three
months ended in Mar. 2026 was $-3.47 Mil. RenovoRx's Revenue for the
three
months ended in Mar. 2026 was $0.56 Mil. Therefore, RenovoRx's EBITDA margin for the quarter that ended in Mar. 2026 was -615.99%.
RenovoRx (NAS:RNXT) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
RenovoRx EBITDA Margin % Related Terms
RenovoRx EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for RenovoRx's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RNXT vs NNVC, KALA, PSTV: EBITDA Margin % Comparison
For the Biotechnology subindustry, RenovoRx's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RenovoRx EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RenovoRx's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where RenovoRx's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RenovoRx (RNXT) has a EBITDA Margin % of -615.99% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on RenovoRx and its competitors. According to the industry distribution chart, RenovoRx ranks #740 out of 944 companies in the Biotechnology industry, placing it in the top 78.4%.
Is RenovoRx's EBITDA Margin % too high?
RenovoRx's current EBITDA Margin % is -615.99%. Based on the distribution chart, RenovoRx ranks #740 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, RenovoRx has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does RenovoRx's EBITDA Margin % compare to NNVC and KALA?
According to the Biotechnology industry distribution chart, RenovoRx ranks #740 out of 944 companies for EBITDA Margin %. This places RenovoRx in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on RenovoRx and its competitors. RenovoRx's current EBITDA Margin % is -615.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RenovoRx stock overvalued right now?
RenovoRx (RNXT) has a current EBITDA Margin % of -615.99%. The current EBITDA Margin % is -615.99%. RenovoRx's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For RenovoRx (RNXT), the current EBITDA Margin % is -615.99% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
31GF Score
Get the complete analysis for RNXT
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RNXT has been successfully added to your 
